Denosumab launched in first indications in Japan through Daiichi Sankyo
This article was originally published in Scrip
Local licensee Daiichi Sankyo has launched Amgen's antibody denosumab for its first indications in Japan, as Ranmark for bone disorders stemming from bone metastases of solid tumours and bone complications of multiple myeloma.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.